| Methods | Consecutive 22 Japanese BU patients (18 males, mean age was 42.8 ± 12.5 y.o.), who were initiated IFX and were followed up more than 12 months, were reviewed. LogMAR, intraocular pressure (IOP), Behçet's disease ocular attack score 24 (BOS24), central foveal thickness (CFT), central choroidal thickness (CCT) at baseline and last visit were evaluated. |
| Results | Mean period between onset and administration and mean period of IFX treatment were 1120±1059 days and 1539±900 days. Mean LogMAR, IOP, BOS24, CFT, and CCT at baseline and last visit were 0.30±0.58, 13.3±5.5 mmHg, 8.2±3.3, 353±130 μm, 289±90 μm, and 0.20±0.79, 12.6±2.6 mmHg, 2.1±1.9, 271±99 μm, 241±72 μm, respectively, with significant improvements in LogMAR, BOS24, CFT, and CCT (P=0.038, P<0.001, P<0.001, P=0.027, respectively). Mean ocular attack during IFX was 0.61 ± 1.3 times/year.Ten patients decreased systemic immunosuppressive agents. Six patients discontinued IFX due to side effect (3 patients), the patient’s request (1 patient), drop out (1 patient), loss of efficiency (1 patient). The continuous rate, remission discontinuation rate, discontinuous rate due to loss of effect, and discontinuous rate due to side effect were 72.8%, 9.1％, 4.5%, 13.6%, respectively. |